Total Reviews: 3
Total Likes: 0
Humate-P is a key intravenous treatment for von Willebrand disease, used when higher VWF levels are needed. It remains essential for major bleeding or surgery, with subcutaneous options in development to improve convenience.
Lysteda is a common first-line option for managing von Willebrand disease, particularly in cases linked to low VWF levels, such as those with type O blood. It offers an effective, non-intravenous alternative to Humate-P.
Desmopressin (DDAVP) works by releasing von Willebrand factor stored in cells near blood vessels, but its effect may be limited if cellular stores are low. Availability has been limited since a 2020 recall, though production is improving through partnerships like HFA and STAQ Pharma, with FDA clearance in 48 states. Insurance coverage remains slow to expand.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.